全文获取类型
收费全文 | 9262篇 |
免费 | 544篇 |
国内免费 | 70篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 141篇 |
妇产科学 | 113篇 |
基础医学 | 1146篇 |
口腔科学 | 118篇 |
临床医学 | 835篇 |
内科学 | 2278篇 |
皮肤病学 | 159篇 |
神经病学 | 754篇 |
特种医学 | 428篇 |
外科学 | 1732篇 |
综合类 | 29篇 |
一般理论 | 5篇 |
预防医学 | 724篇 |
眼科学 | 184篇 |
药学 | 598篇 |
中国医学 | 15篇 |
肿瘤学 | 577篇 |
出版年
2023年 | 51篇 |
2022年 | 106篇 |
2021年 | 269篇 |
2020年 | 151篇 |
2019年 | 245篇 |
2018年 | 304篇 |
2017年 | 188篇 |
2016年 | 189篇 |
2015年 | 255篇 |
2014年 | 318篇 |
2013年 | 445篇 |
2012年 | 755篇 |
2011年 | 717篇 |
2010年 | 466篇 |
2009年 | 426篇 |
2008年 | 636篇 |
2007年 | 686篇 |
2006年 | 557篇 |
2005年 | 621篇 |
2004年 | 532篇 |
2003年 | 471篇 |
2002年 | 496篇 |
2001年 | 73篇 |
2000年 | 66篇 |
1999年 | 82篇 |
1998年 | 80篇 |
1997年 | 63篇 |
1996年 | 65篇 |
1995年 | 64篇 |
1994年 | 50篇 |
1993年 | 31篇 |
1992年 | 38篇 |
1991年 | 45篇 |
1990年 | 23篇 |
1989年 | 32篇 |
1988年 | 21篇 |
1987年 | 22篇 |
1986年 | 14篇 |
1985年 | 26篇 |
1984年 | 21篇 |
1983年 | 9篇 |
1982年 | 18篇 |
1981年 | 9篇 |
1980年 | 10篇 |
1979年 | 9篇 |
1973年 | 10篇 |
1971年 | 7篇 |
1970年 | 7篇 |
1968年 | 11篇 |
1947年 | 8篇 |
排序方式: 共有9876条查询结果,搜索用时 296 毫秒
81.
Hepatitis C infection is associated with autoimmune disorders, such as the production of autoantibodies. Anti-LKM1 and anti-LC1, immunomarkers of type 2 autoimmune hepatitis, have been previously associated with a HCV infection. Anti-Soluble-Liver-Antigen autoantibodies (SLA) are specifically associated with type 1 and type 2 autoimmune hepatitis and more closely related to patients who relapse after steroid therapy. The recent molecular cloning of the soluble liver antigen provides the opportunity to develop more specific tests for the detection of antibodies against it. The aim of this work is to characterize anti-soluble-liver autoantibodies in sera from patients chronically infected by HCV. A recombinant cDNA from activated Jurkat cells coding for the full length tRNP(Ser)Sec/SLA antigen was obtained. ELISA, Western Blot and immunoprecipitation tests were developed and used to search for linear and conformational epitopes recognized by anti-SLA antibodies in sera from patients chronically infected by HCV. Anti-soluble liver antigen antibodies were found in sera from 10.4% of HCV-infected patients. The prevalence was significantly increased to 27% when anti-LKM1 was also present. Most anti-SLA reactivity was directed against conformational epitopes on the antigen. The means titers by ELISA were lower than those obtained in type 2 AIH. The result of autoantibody isotyping showed a subclass restriction to IgG1 and also IgG4. This study shows the presence of anti-SLA antibodies in approximately 10% of HCV infected patients. The prevalence of SLA autoantibodies in HCV infected patients increases when LKM1 autoantibodies are also present. The relationship between the prevalence of this characteristic autoimmune hepatitis autoantibody and the implication of an autoimmune phenomenon in the liver injury of patients chronically infected by HCV needs further investigation. 相似文献
82.
Escherichia coli and Staphylococcus aureus elicit differential innate immune responses following intramammary infection 总被引:6,自引:0,他引:6
Bannerman DD Paape MJ Lee JW Zhao X Hope JC Rainard P 《Clinical and diagnostic laboratory immunology》2004,11(3):463-472
Staphylococcus aureus and Escherichia coli are among the most prevalent species of gram-positive and gram-negative bacteria, respectively, that induce clinical mastitis. The innate immune system comprises the immediate host defense mechanisms to protect against infection and contributes to the initial detection of and proinflammatory response to infectious pathogens. The objective of the present study was to characterize the different innate immune responses to experimental intramammary infection with E. coli and S. aureus during clinical mastitis. The cytokine response and changes in the levels of soluble CD14 (sCD14) and lipopolysaccharide-binding protein (LBP), two proteins that contribute to host recognition of bacterial cell wall products, were studied. Intramammary infection with either E. coli or S. aureus elicited systemic changes, including decreased milk output, a febrile response, and induction of the acute-phase synthesis of LBP. Infection with either bacterium resulted in increased levels of interleukin 1beta (IL-1beta), gamma interferon, IL-12, sCD14, and LBP in milk. High levels of the complement cleavage product C5a and the anti-inflammatory cytokine IL-10 were detected at several time points following E. coli infection, whereas S. aureus infection elicited a slight but detectable increase in these mediators at a single time point. Increases in IL-8 and tumor necrosis factor alpha were observed only in quarters infected with E. coli. Together, these data demonstrate the variability of the host innate immune response to E. coli and S. aureus and suggest that the limited cytokine response to S. aureus may contribute to the well-known ability of the bacterium to establish chronic intramammary infection. 相似文献
83.
Camille Granger Paul Guedeney Camille Arnaud Soulef Guendouz Claire Cimadevilla Mathieu Kerneis Caroline Kerneis Michel Zeitouni Constance Verdonk Camille Legeai Guillaume Lebreton Pascal Leprince Eva Désiré Sabato Sorrentino Johanne Silvain Gilles Montalescot Fanny Hazan Shaida Varnous Richard Dorent 《Transplant international》2021,34(4):721-731
Available data on clinical presentation and mortality of coronavirus disease-2019 (COVID-19) in heart transplant (HT) recipients remain limited. We report a case series of laboratory-confirmed COVID-19 in 39 HT recipients from 3 French heart transplant centres (mean age 54.4 ± 14.8 years; 66.7% males). Hospital admission was required for 35 (89.7%) cases including 14/39 (35.9%) cases being admitted in intensive care unit. Immunosuppressive medications were reduced or discontinued in 74.4% of the patients. After a median follow-up of 54 (19–80) days, death and death or need for mechanical ventilation occurred in 25.6% and 33.3% of patients, respectively. Elevated C-reactive protein and lung involvement ≥50% on chest computed tomography (CT) at admission were associated with an increased risk of death or need for mechanical ventilation. Mortality rate from March to June in the entire 3-centre HT recipient cohort was 56% higher in 2020 compared to the time-matched 2019 cohort (2% vs. 1.28%, P = 0.15). In a meta-analysis including 4 studies, pre-existing diabetes mellitus (OR 3.60, 95% CI 1.43–9.06, I2 = 0%, P = 0.006) and chronic kidney disease stage III or higher (OR 3.79, 95% CI 1.39–10.31, I2 = 0%, P = 0.009) were associated with increased mortality. These findings highlight the aggressive clinical course of COVID-19 in HT recipients. 相似文献
84.
85.
86.
87.
88.
89.
90.
Benjamin Coiffard Philipp M. Lepper Eloi Prud’Homme Florence Daviet Nadim Cassir Heinrike Wilkens Sami Hraiech Frank Langer Pascal A. Thomas Martine Reynaud-Gaubert Robert Bals Hans-Joachim Schäfers Laurent Papazian Frederik Seiler 《American journal of transplantation》2021,21(4):1586-1596
It is unknown if solid organ transplant recipients are at higher risk for severe COVID-19. The management of a lung transplantation (LTx) program and the therapeutic strategies to adapt the immunosuppressive regimen and antiviral measures is a major issue in the COVID-19 era, but little is known about worldwide practice. We sent out to 180 LTx centers worldwide in June 2020 a survey with 63 questions, both regarding the management of a LTx program in the COVID-19 era and the therapeutic strategies to treat COVID-19 LTx recipients. We received a total of 78 responses from 15 countries. Among participants, 81% declared a reduction of the activity and 47% restricted LTx for urgent cases only. Sixteen centers observed deaths on waiting listed patients and eight centers performed LTx for COVID-19 disease. In 62% of the centers, COVID-19 was diagnosed in LTx recipients, most of them not severe cases. The most common immunosuppressive management included a decreased dose or pausing of the cell cycle inhibitors. Remdesivir, hydroxychloroquine, and azithromycin were the most proposed antiviral strategies. Most of the centers have been affected by the COVID-19 pandemic and proposed an active therapeutic strategy to treat LTx recipients with COVID-19. 相似文献